Cas:269084-19-7 Diethyl [2-(2-methylphenyl)ethyl]malonate manufacturer & supplier

Chemical Name:Diethyl [2-(2-methylphenyl)ethyl]malonate

CAS.NO:269084-19-7

Synonyms:Diethyl [2-(2-methylphenyl)ethyl]malonate

Molecular Formula:C₁₆H₂₂O₄

Molecular Weight:278.34300

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:52.60000

Exact Mass:278.15200

LogP:2.67000

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Diethyl [2-(2-methylphenyl)ethyl]malonate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Diethyl [2-(2-methylphenyl)ethyl]malonate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Diethyl [2-(2-methylphenyl)ethyl]malonate Use and application,Diethyl [2-(2-methylphenyl)ethyl]malonate technical grade,usp/ep/jp grade.

Related News: Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access. Diethyl [2-(2-methylphenyl)ethyl]malonate manufacturer Under the terms of this agreement, Inceptua will support Onconova through the pre-approval provision of intravenous rigosertib initially into a number of countries including: Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, Portugal, South Africa, Spain, and the UK. Diethyl [2-(2-methylphenyl)ethyl]malonate supplier Delta moved the date up after the US State Department warned that people should not travel to China due to concerns about the spread of coronavirus, which was first discovered in Wuhan, Hubei province, in December. Diethyl [2-(2-methylphenyl)ethyl]malonate vendor Under the terms of this agreement, Inceptua will support Onconova through the pre-approval provision of intravenous rigosertib initially into a number of countries including: Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, Portugal, South Africa, Spain, and the UK. Diethyl [2-(2-methylphenyl)ethyl]malonate factory Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access.